306 related articles for article (PubMed ID: 30483806)
41. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
[TBL] [Abstract][Full Text] [Related]
42. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
43. Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients.
Heublein S; Mayr D; Egger M; Karsten U; Goletz S; Angele M; Gallwas J; Jeschke U; Ditsch N
J Exp Clin Cancer Res; 2015 May; 34(1):50. PubMed ID: 25986064
[TBL] [Abstract][Full Text] [Related]
44. Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases.
Chen MN; Zeng D; Zheng ZQ; Li Z; Wu JL; Jin JY; Wang HJ; Huang CZ; Lin HY
J Vis Exp; 2019 May; (147):. PubMed ID: 31157790
[TBL] [Abstract][Full Text] [Related]
45. Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.
Lin Y; Zhou X; Peng W; Wu J; Wu X; Chen Y; Cui Z
BMC Cancer; 2021 Sep; 21(1):1062. PubMed ID: 34565331
[TBL] [Abstract][Full Text] [Related]
46. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
47. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer.
Merikhian P; Ghadirian R; Farahmand L; Mansouri S; Majidzadeh-A K
Expert Rev Anticancer Ther; 2017 Jul; 17(7):607-613. PubMed ID: 28597750
[TBL] [Abstract][Full Text] [Related]
48. Bioinformatics analysis of potential prognostic biomarkers among Krüppel-like transcription Factors (KLFs) in breast cancer.
Cheng L; Shi L; Dai H
Cancer Biomark; 2019; 26(4):411-420. PubMed ID: 31640084
[TBL] [Abstract][Full Text] [Related]
49. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
50. SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.
Chan HJ; Li H; Liu Z; Yuan YC; Mortimer J; Chen S
Oncotarget; 2015 Sep; 6(28):25815-27. PubMed ID: 26158350
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of mucin expression profiles in breast carcinoma with signet ring cells: a clinicopathological study.
Ohashi R; Hayama A; Yanagihara K; Yamashita K; Sakatani T; Takei H; Naito Z
Diagn Pathol; 2016 Nov; 11(1):131. PubMed ID: 27846863
[TBL] [Abstract][Full Text] [Related]
52. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
53. Interaction Between MUC1 and STAT1 Drives IFITM1 Overexpression in Aromatase Inhibitor-Resistant Breast Cancer Cells and Mediates Estrogen-Induced Apoptosis.
Escher TE; Lui AJ; Geanes ES; Walter KR; Tawfik O; Hagan CR; Lewis-Wambi J
Mol Cancer Res; 2019 May; 17(5):1180-1194. PubMed ID: 30655323
[TBL] [Abstract][Full Text] [Related]
54. A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
Wu G; Kim D; Kim JN; Park S; Maharjan S; Koh H; Moon K; Lee Y; Kwon HJ
Theranostics; 2018; 8(1):78-91. PubMed ID: 29290794
[No Abstract] [Full Text] [Related]
55. Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer.
Nath S; Roy LD; Grover P; Rao S; Mukherjee P
Pancreas; 2015 Aug; 44(6):909-17. PubMed ID: 26035123
[TBL] [Abstract][Full Text] [Related]
56. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
[TBL] [Abstract][Full Text] [Related]
57. Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer.
Sato K; Akimoto K
Clin Breast Cancer; 2017 Jun; 17(3):e135-e142. PubMed ID: 27986439
[TBL] [Abstract][Full Text] [Related]
58. Biphasic Alterations in Expression and Subcellular Localization of MUC1 in Pancreatic Ductal Carcinogenesis in Syrian Hamsters.
Kitahashi T; Takahashi M; Imai T
Pancreas; 2015 Jan; 44(1):76-86. PubMed ID: 25036908
[TBL] [Abstract][Full Text] [Related]
59. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
60. Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer.
Cui X; Jing X; Yi Q; Long C; Tian J; Zhu J
Oncotarget; 2017 Dec; 8(67):111444-111455. PubMed ID: 29340066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
